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a b s t r a c t
Nucleos(t)ide analogues that inhibit hepatitis B virus (HBV) DNA replication are typically used as
monotherapy for chronically infected patients. Treatment with a nucleos(t)ide analogue eliminates most
HBV DNA replication intermediates and produces a gradual decline in levels of covalently closed circular
DNA (cccDNA), the template for viral RNA synthesis. It remains uncertain if levels of cccDNA decline
primarily through hepatocyte death, or if loss also occurs during hepatocyte mitosis. To determine if
cccDNA survives mitosis, growing ducklings infected with duck hepatitis B virus (DHBV) were treated
with the nucleoside analogue, Entecavir. Viremia was suppressed at least 105-fold, during a period when
average liver mass increased 23-fold. Analysis of the data suggested that if cccDNA synthesis was
completely inhibited, at least 49% of cccDNA survived hepatocyte mitosis. However, there was a large
duck-to-duck variation in cccDNA levels, suggesting that low level cccDNA synthesis may contribute to
this apparent survival through mitosis.
Crown Copyright & 2013 Published by Elsevier Inc. All rights reserved.
Introduction
Hepadnaviruses establish a productive infection of hepatocytes
by the conversion of the viral relaxed circular DNA (rcDNA)
genome to its episomal form, covalently closed circular DNA
(cccDNA). cccDNA, found in the hepatocyte nucleus, serves as
the template for the transcription of viral mRNAs, including the
pregenomic RNA, which is subsequently reverse transcribed in the
cytoplasm to form replicative intermediate (RI) DNA (Summers
and Mason, 1982). RI DNA synthesis takes place within viral
nucleocapsids, which are either enveloped at the ER and released
from infected hepatocytes as progeny virus, or migrate to the
nucleus to increase the copy number of cccDNA (Wu et al., 1990).
cccDNA does not undergo semi-conservative DNA synthesis
(Tuttleman et al., 1986) but appears stable in non-dividing hepa-
tocytes (Moraleda et al., 1997; Zhu et al., 2001). For instance,
cccDNA has also been shown to persist at low levels in the liver
during occult hepatitis B virus (HBV) (Reviewed by Raimondo et al.
(2010)) and duck hepatitis B virus (DHBV) infections (Le Mire et al.,
2005; Reaiche et al., 2010), without clear signs of ongoing viral
DNA replication.
At the peak of a hepadnavirus infection, whether transient or
chronic, there are multiple copies of cccDNA in the nucleus of each
infected cell, with the cccDNA copy number estimates in individual
infected hepatocytes ranging from 1 to 50 (Jilbert et al., 1992;
Kajino et al., 1994; Miller and Robinson, 1984; Zhang et al., 2003).
cccDNA binds endogenous histone proteins (Guo et al., 2007; Levrero
et al., 2009; Pollicino et al., 2006) and exists as a mini-chromosome.
The half-life of cccDNA in infected adult liver appears prolonged, and
has been suggested, but not proven, to be identical to that of the
infected hepatocytes themselves (Fourel et al., 1994; Luscombe et al.,
1996; Zhang and Summers, 2000). Infected hepatocytes are elimi-
nated from the liver primarily as the result of targeting by the
antiviral immune response, as hepadnavirus infection per se does not
seem to be intrinsically cytopathic. Hepatocytes targeted by the
immune response appear, for the most part, to be replaced by
division of surviving hepatocytes (Jilbert et al., 1992; Summers
et al., 2003), rather than hepatic stem/progenitor cells.
Because cccDNA deﬁnes the infected state of a hepatocyte, there
has been considerable interest in how this molecule might be
eliminated therapeutically from patients with chronic HBV infection.
Nucleos(t)ide analogues block synthesis of the RI DNA that is
required to synthesize new cccDNA, but elimination of existing
cccDNA is thought to require, either directly or indirectly, the death
of infected hepatocytes. If cccDNA were completely lost during
hepatocyte mitosis (e.g., if it failed to be reincorporated into the
nucleus when the nuclear membrane reforms during mitosis),
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elimination of an average of 30 copies of cccDNA from a fully infected
adult liver would require a minimum of 0.7 liver equivalents of
hepatocyte death, and compensatory proliferation, even assuming
selective death of infected hepatocytes. Likewise, if cccDNAwere able
to fully survive hepatocyte mitosis, elimination of cccDNA would
require a minimum of 2.7 liver equivalents of hepatocyte death
and compensatory proliferation (Mason and Litwin, 2002; Summers
et al., 2003). The time to achieve 2.7 liver equivalents of hepatocyte
turnover, especially in a healthy HBV carrier, might amount to many
years. Thus, it is important to know the fate of cccDNA during
hepatocyte mitosis, as this may be a major factor in the elimination
of cccDNA. The behaviour of cccDNA during mitosis has been difﬁcult
to address because levels of hepatocyte turnover in HBV-infected
adults are generally low, and difﬁcult to quantify.
In a study of woodchucks chronically infected with woodchuck
hepatitis virus (WHV), treatment with the nucleoside analogue,
L-FMAU, caused declines in RI and cccDNA, which began almost as
soon as treatment was started. However, there was a signiﬁcant lag
in the emergence of uninfected hepatocytes (Zhu et al., 2001).
Estimates of the turnover rate of woodchuck hepatocytes, based on
proliferating cell nuclear antigen (PCNA) staining of hepatocytes in S
phase, suggested that cccDNA survives mitosis and is randomly
distributed to progeny cells during nucleoside analogue therapy,
and that its loss might be due entirely to hepatocyte death. By this
model, signiﬁcant numbers of uninfected hepatocytes only begin to
appear as the cccDNA copy number decreases to 1 copy per cell,
where mitosis of an infected hepatocyte gives rise to one infected
and one uninfected hepatocyte (Zhu et al., 2001). If, on the other
hand, WHV cccDNA were lost at mitosis, uninfected hepatocytes
should have appeared earlier during nucleoside analogue therapy, as
soon as the levels of cccDNA began to decline.
However, estimates of hepatocyte death and compensatory
proliferation based on PCNA staining may be highly inaccurate,
due to incorrect assumptions about the length of S phase and of
the cell cycle of hepatocytes. In addition, RI DNA present in the
cytoplasm of infected hepatocytes might survive mitosis, and low
levels of cccDNA synthesis during monotherapy might compensate
for hypothetical cccDNA loss during hepatocyte mitosis, thereby
giving the appearance of cccDNA survival.
To begin to sort this out, we have sought a better way to
estimate hepatocyte proliferation, in order to provide a clearer
evaluation of the behaviour of cccDNA during mitosis; in parti-
cular, during antiviral therapy. This can most easily be achieved by
studying infection in a growing liver in which hepatocyte prolif-
eration might be accurately determined, and with minimal con-
current cell death. To do this we infected 2-day-old ducks with
DHBV, treated the ducks with the nucleoside analogue Entecavir
(ETV), to inhibit formation of RI DNA and new synthesis of cccDNA,
and then measured levels of cccDNA during a period of rapid
hepatocyte proliferation and liver growth.
Results
Experimental approach
To determine how hepatocyte proliferation affects levels of
cccDNA during antiviral therapy, we took advantage of the fact
Table 1
Liver weight, levels of BrdU incorporation and markers of DHBV infection in the serum and liver of ducks treated with ETV.
Days p.i.a Duck # Liver
weight (g)
% of BrdU-positive
hepatocytesb
% of DHBsAg-positive
hepatocytesc
Serum total DHBV
DNA (copies/mL)d
Liver total DHBV
DNA (copies/hepatocyte)e
Liver cccDNA
(copies/hepatocyte)e
1 1 3.4 11.3 o0.001 1.6Eþ04 0.79 0.73
2 3.3 NDf 0.005 7.0Eþ03 1.63 0.82
3 3.6 ND 0.02 6.1Eþ03 1.31 0.47
4 3.8 7.2 o0.001 4.8Eþ03 3.29 0.64
5 3.5 11 0.01 1.66Eþ04 2 0.93
7 6 13.4 5 1.7 7.4Eþ04 1.71 0.45
7 11.1 8.1 3 2.6Eþ04 1.69 0.22
8 11.5 9 0.8 1.0Eþ04 1 0.28
14 9 25 4.2 0.16 4.1Eþ03 0.114 0.057
10 30 4.6 1.4 1.2Eþ04 1.1 0.30
11 30 3.9 1.04 4.5Eþ03 0.043 0.014
21 12 50 6.9 0.28 4.0Eþ03 0.043 0.0186
13 42.8 11.8 0.36 6.1Eþ03 0.114 0.057
14 60 4.9 0.4 2.9Eþ03 0.029 0.023
28 15 56.9 2.4 0.25 2.4Eþ03 0.014 0.0057
16 64.7 1.7 0.55 4.8Eþ03 0.129 0.061
17 59 2 5.2 1.8Eþ04 1.37 1.34
35 18 76.5 3.7 0.07 3.1Eþ03 0.0086 0.0071
19 64.8 2.3 0.28 2.9Eþ03 0.0029 0.00143
20 66 1.6 1.4 5.3Eþ03 0.2 0.147
42 21 90.7 3.7 0.006 3.5Eþ03 0.37 0.054
22 68.4 3.2 0.01 1.5Eþ03 0.0057 0.00571
23 88.1 2 2.1 5.8Eþ03 0.139 0.086
a Treatment of ducks with ETV (1 mg/kg body weight/day) commenced 2 h after DHBV infection.
b BrdU-positive hepatocytes were detected in the liver by immunoperoxidase staining using anti-BrdU antibodies and are expressed as a percentage of total
haematoxylin stained hepatocyte nuclei as described in Materials and Methods.
c DHBsAg-positive hepatocytes were detected in the liver by immunoperoxidase staining using anti-DHBV pre-S monoclonal antibodies and are expressed as a
percentage of total haematoxylin stained hepatocyte nuclei as described in Materials and Methods.
d Levels of total DHBV DNA were detected by qPCR in 200 μL samples of serum and are expressed as copies per millilitre as described in Materials and Methods.
e Levels of total DHBV DNA and cccDNA were detected by qPCR in 150 ng samples of liver DNA and are expressed as copies per hepatocyte assuming that each cell
contains 2.8 pg of DNA and hepatocytes comprise 70% of liver cells as described in Materials and Methods.
f ND: not detected.
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that ducklings grow very rapidly, reaching mature body weight in
only a few months. Therefore, if we could conﬁrm that expansion
of the hepatocyte population during this period was primarily due
to self-replication of hepatocytes, as in other species (Alison, 2003;
Kennedy et al., 1995), and was not altered by DHBV infection, we
would be able to assess the effects of hepatocyte proliferation on
the survival of cccDNA.
Thus, 23, 2-day-old ducks were infected with 3109 viral
genome equivalents of DHBV, sufﬁcient to deliver 1 rcDNA
containing DHBV virion per hepatocyte. The ducks were then
treated orally with ETV at 1 mg/kg/day for up to 42 days. The ﬁrst
dose of ETV was given at 2 h post-infection (p.i.) to inhibit new
viral DNA synthesis. ETV, a guanosine nucleoside analogue, was
not expected to signiﬁcantly inhibit conversion of virion rcDNA to
cccDNA during initiation of infection but was expected to strongly
inhibit formation of RI DNA and new synthesis of cccDNA (Foster
et al., 2005; Kock and Schlicht, 1993; Lien et al., 1987). Groups of
ducks were autopsied at various time points between 1 and 42
days p.i. (Table 1).
Liver growth via hepatocyte proliferation
Bromodeoxyuridine (BrdU) was injected 8 h before autopsy to
assess hepatocyte proliferation via labelling of hepatocytes in the S
phase of the cell cycle (Table 1). Cells in S phase were visualized by
immunoperoxidase staining using anti-BrdU monoclonal antibo-
dies. S-phase labelling was seen predominantly in hepatocytes (h;
Fig. 1H), which comprise 70% of liver cells. Labelled hepatocytes
occurred mainly in pairs, suggesting that division had taken place
following the S-phase labelling with BrdU. Some BrdU-labelling
was also seen in non-hepatocytes (n-h; Fig. 1H). Although BrdU is
a marker of DNA synthesis, detection of BrdU incorporated due to
DNA repair is highly unlikely as the rate of incorporation is
considerably lower than that of BrdU incorporation due to cell
division. For the detection of BrdU in DNA repair, BrdU is required
to be administered for 24–48 h prior to staining. However,
incorporation of BrdU during cell division is achieved in 8 h
(Selden et al., 1994; Taupin, 2007). Hepatocyte labelling was
scattered throughout the liver lobule except, perhaps, around the
central vein (CV; Fig. 1). A predominantly periportal labelling, as
might be expected during hepatocyte replacement from faculta-
tive stem cells (Kuhlmann and Peschke, 2006), was not observed.
These data support the conclusion that, as in other species (Nejak-
Bowen et al., 2013) the hepatocyte population of ducks expands,
during liver growth, primarily by self-replication. As illustrated in
Fig. 1 and summarized in Fig. 2, the S phase labelling of hepato-
cytes declined as the mass of the liver of the ducks increased,
consistent with the approximately linear growth rate of the liver.
To determine if DHBV infection altered the ability of hepato-
cytes to enter S phase, we ﬁrst assayed sections of liver tissue for
DHBV surface antigen (DHBsAg)-positive and DHBV core antigen
(DHBcAg)-positive hepatocytes by immunoperoxidase staining. As
in a previous study of ducks infected with DHBV and immediately
placed on ETV therapy, we found that DHBsAg-positive hepato-
cytes were, for the most part, at least 10-fold less frequent than
expected from cccDNA copy number estimates (Table 1), which
Fig. 1. Immunoperoxidase and immunoﬂuoresence staining of BrdU-positive (proliferating) hepatocytes (Panels A–H) and both DHBsAg- and BrdU-positive hepatocytes
(Panel I) in ethanol acetic acid (EAA) ﬁxed duck liver sections. Panel (A) Duck 1 at day 1 p.i.; (B) Duck 6 at day 7 p.i.; (C) Duck 9 at day 14 p.i.; (D) Duck 14 at day 21 p.i.;
(E) Duck 15 at day 28 p.i.; (F) Duck 20 at day 35 p.i.; (G) Duck 23 at day 42 p.i.; and (H) Ampliﬁed area from Panel F showing BrdU-positive hepatocytes (h) and non-
hepatocytes (n-h). Counterstained with haematoxylin; PT, portal tract; and CV, central vein. Panel (I) Dual immunoﬂuorescence staining of DHBsAg-positive (green) and
BrdU-positive (red) hepatocytes. Dual stained cells are indicated with arrows. Magniﬁcation Panels A–G and I¼400 and Bar¼100 μM. Magniﬁcation Panel H¼1200 and
Bar¼50 μM. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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provide a more reliable indication of infected cell number (Foster
et al., 2005). Similar results were found in assays for DHBcAg-
positive hepatocytes (not shown). Since all hepatocytes are cap-
able of expressing these DHBV antigens in ducklings that are not
drug-treated (Jilbert et al., 1996; Meier et al., 2003), we suspect
that antigen detection may, in most hepatocytes, require cccDNA
copy number ampliﬁcation, which should, in theory, have been
completely inhibited by ETV in the current study.
To determine how viral antigen expression correlated with
BrdU labelling, we focussed on DHBsAg-positive hepatocytes and
carried out dual immunoﬂuorescence staining of EAA-ﬁxed liver
tissue sections with anti-DHBsAg and anti-BrdU antibodies (Fig. 1,
Panel I). As summarized in Table 2, the percentage of DHBsAg-
positive hepatocytes that were also BrdU-positive was similar to
the percentage of total BrdU-positive hepatocytes, suggesting that
expression of DHBsAg was not associated with inhibition of entry
into S phase; the slightly higher incidence of BrdU-labelling in
DHBsAg-positive hepatocytes did not reach statistical signiﬁcance.
These data support the notion that DHBV infection per se does not
inhibit hepatocyte proliferation.
Survival of cccDNA during liver growth
As shown in Table 1, serum titres of DHBV DNA were in the
range of 103–105/mL, at least 105-fold below levels in untreated
ducklings (Foster et al., 2003). In addition, after day 1 p.i., the total
amount of DHBV DNA in the liver ranged from 0.001 to 1.7 copies
per cell (Table 1), at least 100-fold lower than in experimentally
DHBV-infected and untreated ducks of a similar age (data not
shown Foster et al., 2003). Thus, DHBV replication, as assessed by
quantitative PCR (qPCR), was strongly inhibited by ETV. Average
levels of cccDNA varied from 0.47 to 0.93 copies per hepatocyte at
day 1 p.i., and from 0.28 to 0.45 copies per hepatocyte at day 7 p.i.,
indicating minimal duck-to-duck variability in the delivery of the
inoculum and the establishment of DHBV infection. Unexpectedly,
the duck-to-duck variability in levels of cccDNA increased with
time (Table 1; Fig. 3).
The data were compared to predicted declines in cccDNA per
hepatocyte, assuming that cccDNA synthesis is completely inhib-
ited, that cccDNA either survives or is lost during hepatocyte
mitosis, and that cell death does not occur in the growing liver
(Fig. 3). If cccDNA survives mitosis, cccDNA levels per hepatocyte
should drop inversely with the increase in liver size; if cccDNA is
lost during mitosis, they would drop inversely with the square of
the increase in liver size (see Materials and Methods). Although
there is signiﬁcant variation from duck-to-duck, all but one of the
data points, after day 1 p.i., fall above the predicted levels for loss
of cccDNA at mitosis (Fig. 3). Indeed, a power trend line of the data
(solid line) ﬁts closely with the model for cccDNA survival during
mitosis. We also considered the contribution of cell death. Apop-
totic indices in individual ducks were counted in haematoxylin
and eosin stained sections (data not shown) and were found to be
in the range of 0.005–0.2%, which might contribute a maximum
daily cell death rate of about 2% (Goetz et al., 2011). However, cell
death would decrease levels of cccDNA and decrease the relative
contribution of loss of cccDNA at mitosis. This would increase the
statistical signiﬁcance of the model for cccDNA survival through
mitosis, as discussed later. This would also be the case if
there were spontaneous intracellular decay of cccDNA in non-
dividing hepatocytes. However, we think that this is unlikely to be
a signiﬁcant factor in the current short-term experiment since
the half-life of cccDNA in primary, non-dividing, woodchuck
Fig. 2. Graphical representation of BrdU-positive hepatocytes and liver mass. As
the ducks aged the percentage of BrdU-positive (proliferating) hepatocytes
declined, consistent with the decline in the rate of liver growth.
Table 2
Percentage of DHBsAg-positive hepatocytes also positive for BrdU.
Days p.i. Duck # % of DHBsAg-
positive
hepatocytesa
% of BrdU-
positive
hepatocytesb
% of DHBsAg-positive
hepatocytes also
positive for BrdUc
7 6 0.7 7 13.1
14 10 1.2 3.5 7.3
28 17 1.1 1.7 4.2
35 20 0.8 1.3 2.5
a DHBsAg-positive hepatocytes, detected by immunoﬂuorescence staining
using anti-DHBV pre-S monoclonal antibodies and ﬂuorescently labelled secondary
antibodies Alexa Fluor 488 (green), are expressed as a percentage of total DAPI
stained hepatocyte nuclei (blue) as described in Materials and Methods.
b BrdU-positive hepatocytes, detected by immunoﬂuorescence staining using
anti-BrdU antibodies and ﬂuorescently labelled secondary antibodies Alexa Fluor
594 (red), expressed as a percentage of total DAPI stained hepatocyte nuclei (blue)
as described in Materials and Methods.
c The percentage of DHBsAg-positive (green) hepatocytes also positive for BrdU
(red) was determined by dual immunoﬂuorescence staining with anti-DHBV pre-S
and anti-BrdU antibodies, as described in Materials and Methods.
Fig. 3. Decline in cccDNAwith day p.i. The fractional decline in cccDNAwas plotted
by dividing the cccDNA copy number per hepatocyte at each time point by the
average cccDNA per hepatocyte at day 1 p.i. (cf., Table 1). The power trend line to
predicted changes in cccDNA per hepatocyte has been added to summarize the data
(solid line). Predicted declines in cccDNA per hepatocyte due to increasing liver
mass were calculated for each duck assuming that cccDNA was initially in infected
hepatocytes at a copy number of one and that it either did, or did not, survive
mitosis. If cccDNA survived mitosis, division of an infected hepatocyte would give
rise to one infected and one uninfected hepatocyte, and the fraction of infected
hepatocytes would decline inversely with the increase in cell mass (upper dashed
line). If cccDNA were lost at mitosis, then division of each infected hepatocyte
would give rise to two uninfected hepatocytes, and the fraction of infected
hepatocytes would decline inversely with the square of the infected cell mass
(lower dashed line).
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hepatocytes appears to exceed 30 days (Moraleda et al., 1997; Zhu
et al., 2001). These considerations might appear to rule out the
model for loss of cccDNA at mitosis. However, the increasing
amount of duck-to-duck variation at later time points suggests a
more complex interpretation and raises the possibility that
cccDNA synthesis during nucleoside analogue monotherapy may
be strongly but not completely inhibited.
Discussion
To analyse our data, we ﬁrst compared our results to models
where cccDNA synthesis is completely inhibited by ETV and either
survives or is lost, to varying degrees, during mitosis. The analysis
is described in Materials and Methods and illustrated in
Supplementary Fig. S1. This analysis ruled out a loss of more than
49% of cccDNA per round of mitosis (p¼0.0245); that is, assuming
that cccDNA synthesis was completely inhibited, at least 49% of
cccDNA survived mitosis. The p-value is reduced to 0.0015 if we
assume a maximum estimated daily cell death rate of 2% (data not
shown).
However, this model does not explain the signiﬁcant duck-to-
duck variation in cccDNA levels at later time points, especially
considering that cccDNA measurements were reproducible and
that cccDNA levels per hepatocyte varied consistently with mea-
surements of total DHBV DNA per hepatocyte, made using a
different PCR primer set (Table 1; Fig. 3). Thus, the duck-to-duck
variation appears real. The basis for this variability has not been
determined. One possibility, consistent with the data, is that
nucleoside analogue monotherapy is highly effective but still
shows minor individual variations in efﬁciency. From this per-
spective, it is important to note that the level of cccDNA in some
ducklings was more consistent with loss of some or all cccDNA at
mitosis (Fig. 3), while in others it actually appeared to exceed the
level for survival through mitosis (Fig. 3).
Thus, the overall appearance that cccDNA survives mitosis
might actually be the result of survival through mitosis of low
levels of the RI DNA precursor to cccDNA. The fact that serum
DHBV DNA (virus) is detected during monotherapy is consistent
with the notion that low level RI DNA in the hepatocyte cytoplasm
might maintain a low level of cccDNA synthesis in the liver.
However, because liver growth was approximately linear during
the course of the experiment, the fraction of infected cells that
divide decreases each day, as would the need for new cccDNA
synthesis resulting from loss of cccDNA at mitosis. Overall, this
would amount to a 100-fold decrease in the amount of new
cccDNA synthesis between day 2 and day 42 p.i. that would be
required to maintain a constant level of cccDNA in the liver. Thus,
maintenance of a constant level of cccDNA in the liver by de novo
cccDNA synthesis would be most consistent with a model in which
RI DNA is passed directly to progeny hepatocytes during mitosis,
allowing cccDNA synthesis, rather than a model in which cccDNA
is predominately maintained by new infections.
Interestingly, a mechanism by which hepadnavirus cccDNA
might efﬁciently survive mitosis has not been found. Some viruses,
including human papilloma virus (HPV), Epstein-Barr virus (EBV)
and Kaposi's sarcoma herpes virus (KSHV) are capable of tethering
episomal DNA to host chromosomes during mitosis, helping to
maintain persistent virus infection (Dresang et al., 2009; Feeney
and Parish, 2009; Wang and Sugden, 2008). All of these viruses
use speciﬁc viral proteins to aid in tethering. At present, there is no
evidence that hepadnaviruses have the capacity to tether cccDNA
to host chromosomes.
In summary, nucleoside analogue monotherapy administered
during a period of rapid growth of DHBV-infected ducklings leads
to an overall trend suggesting that cccDNA survives mitosis.
However, the large duck-to-duck variation seen at later times
suggests a more complex picture that may include continuing low
level synthesis of cccDNA. A rigorous test of this idea might be
achieved by combination therapy with ETV and another effective
antiviral drug, such as Tenofovir.
Materials and methods
Animals
DHBV-negative Pekin-Aylesbury ducks (Anas domesticus platyr-
hynchos) were housed in the Veterinary Services Division of SA
Pathology (formerly the Institute of Medical and Veterinary
Science), Adelaide, South Australia. Animal handling protocols
and standard operating procedures were approved by the Animal
Ethics Committees of the SA Pathology/Central Health Network
and the University of Adelaide in accordance with the guidelines of
the National Health and Medical Research Council (NHMRC) of
Australia.
Virus inoculums
Two-day-old ducks were injected with 300 μL of a pool of
DHBV-positive serum, obtained by combining sera from congeni-
tally infected ducks, and containing 9.5109 DHBV genomes/mL
(Jilbert et al., 1996).
Antiviral treatment
Entecavir (ETV), provided by Bristol-Myers Squibb Pharmaceu-
ticals, was dissolved in deionised H2O at a concentration of 1 mg/
mL. ETV was administered orally to the treated group at 1 mg/kg
body weight/day from 2 h p.i. until autopsy.
Collection and analysis of liver tissue
Eight hours prior to autopsy, ducks were injected intra-
peritoneally with BrdU (Sigma-Aldrich) dissolved in H2O, at a
dose of 25 mg/kg body weight. Ducks were euthanized with by
injection of sodium pentobarbital. Serum, obtained by cardiac
puncture, was tested by qPCR for DHBV DNA. Livers were resected
and weighed, then split into three portions. One sample was ﬁxed
in 10% formalin in phosphate-buffered saline, for histology, and
another in ethanol/acetic acid (EAA, 3:1 v/v), for immunoperox-
idase and immunoﬂuorescence staining. The ﬁxed tissues were
then dehydrated and embedded in parafﬁn wax, as previously
described (Foster et al., 2005). The remaining sample was snap-
frozen in liquid nitrogen and stored at 80 1C for subsequent DNA
extraction.
Sections of EAA-ﬁxed liver were rehydrated, stained by hae-
matoxylin and eosin and examined for the presence of apoptotic
hepatocytes. Sections of EAA-ﬁxed liver were also rehydrated and
examined by immunoperoxidase staining with anti-DHBV pre-S
monoclonal antibodies (1H1; subtype IgG1) (Pugh et al., 1995), to
determine the percentage of DHBsAg-positive hepatocytes (Miller
et al., 2004). These EAA-ﬁxed sections were also immunoperox-
idase stained to detect cells that incorporated BrdU during the
S-phase of cell division, using anti-BrdU monoclonal antibodies
(subtype IgG2a, Roche, CAT #1170376) as previously described
(Mason et al., 1994), with visualization using HRP labelled sheep
anti-mouse antibodies (GE Healthcare UK limited, CAT #NA931V)
and diaminobenzidine. Cell counts were performed using an
eyepiece graticule with a 250250 mm2 grid, as previously
described (Reaiche et al., 2010).
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Dual staining for both DHBsAg-positive and BrdU-positive
hepatocytes was performed by immunoﬂuorescence staining of
EAA-ﬁxed liver sections using anti-DHBV pre-S (1H1; subtype
IgG1) (Pugh et al., 1995) and anti-BrdU antibodies (subtype IgG2a;
Roche, CAT #1170376), respectively. Visualization was achieved
using sheep anti-mouse anti-IgG1-Alexa Fluor 488 (green) and
sheep anti-mouse IgG2a-Alexa Fluor 594 (red) ﬂuorescently
labelled secondary antibodies (Invitrogen). The counts are
expressed as a percentage of total 4′,6-Diamidino-2-phenylindole
dihydrochloride (DAPI; blue; Sigma-Aldrich) counter-stained
hepatocyte nuclei. The ﬂuorescent secondary antibodies and the
counter stain were carefully selected for their excitation wave-
lengths to avoid possible cross-over. Alexa Fluor 488 (green) has
an excitation wavelength of 488 nm and Alexa Fluor 594 (red) has
an excitation wavelength of 594 nm and DAPI (blue) has an
excitation wavelength of 340 nm. All ﬂuorescence microscopy
was performed using a Nikon TiE inverted 4 ﬂuorescence micro-
scope using the BrightLine single-band ﬁlter sets (FITC-3540C8-
NTE-ZERO, TxRed-4040C-NTE-ZERO and DAPI-5060C-NTE-ZERO)
with a 20 objective lens. Images of the emitted light were
collected using a monochrome 12-bit cooled charge-coupled
device camera with a maximum 10 resolution of 12801024
(DS-Qi1; Nikon). Individual cell counts for both DHBsAg-positive
and BrdU-positive hepatocytes were performed automatically
using the ‘Object Counting’ feature of NIS Elements AR v. 3.22.
Counts for cells that were dually stained were performed
manually.
Extraction and qPCR analysis of DHBV DNA from liver and serum
DNA was extracted from 25 mg of liver tissue (Reaiche et al.,
2010) and RNase A treated, using the ChargeSwitch gDNA mini
tissue kit as per the manufacturer's instructions (Invitrogen, CAT
#CS11204). DNA yields were determined by UV spectrophotome-
try. DNA was also extracted from 200 μL of serum using the
ChargeSwitch gDNA serum kit as per the manufacturer's instruc-
tions (Invitrogen, CAT #CS11040). Primers for the detection of total
DHBV DNA in liver and serum were situated within the polymer-
ase open reading frame (P1 – 5′CTAAGCATCACTTGGGGAAA
(nucleotide position 423–442), P2 – 3′GCTGGAGTCAAATATTTCCAA
(nucleotide position 576–557) based on the Australian DHBV strain
(Genbank AJ006350; (Triyatni et al., 2001)). Primers for the
detection of cccDNA in the liver spanned the cohesive overlap
region of the DHBV genome P3 – 5′CCTGATTGGACGGCTCTTAC
(nucleotide position 2462–2481), P4 – 3′AAAGGTACAGT-
CAAGGCTGA (nucleotide position 2618–2599) (Reaiche et al.,
2010). To quantify the qPCR assays, the plasmid pBL4.81,
containing a monomer of the full-length genome of AusDHBV
(Triyatni et al., 2001), was used to construct a standard curve.
Plasmid samples contained 101–108 copies of EcoRI digested
pBL4.81 in the presence of 150 ng of normal duck liver (NDL)
DNA, as carrier. Samples of duck liver DNA extracted from autopsy
liver tissue were also digested with EcoRI overnight at 37 1C and
diluted to 150 ng of total DNA per reaction before use in qPCR. All
qPCR reactions were performed using SYBR green PCR master mix
(Applied Biosystems, CAT #4309155) and an Applied Biosystems
StepOne plus PCR machine. The conditions for qPCR included an
initial denaturation step of 10 min at 95 1C. Ampliﬁcation con-
sisted of 40 cycles of, 15 s at 95 1C followed by 1 min at 60 1C. The
data were analysed using Applied Biosystems StepOne plus soft-
ware. Levels of total DHBV DNA and cccDNA were expressed as
copies per hepatocyte assuming that each cell contains 2.8 pg of
DNA (Krishan et al., 2005; Tiersch and Wachtel, 1991) and
hepatocytes comprise 70% of liver cells.
Statistical analysis of data
One analytic and two simulation models, “single copy” and
“Poisson” were constructed for comparison with the data. In the
models, it was assumed that antiviral therapy with ETV completely
inhibited cccDNA synthesis. The analytic model and the “single
copy” simulation model were based on the assumption that each
infected hepatocyte had exactly 1 copy of cccDNA, formed from
the inoculated virus. The “Poisson” simulation model was con-
structed based on the assumption that infected hepatocytes had a
Poisson-distributed number (including zero) of copies of cccDNA.
All three models were normalized to the amount of cccDNA
detected at day 1 p.i. (The code for the “single copy” and “Poisson”
models is available upon request).
Analytic model
This model was used for a simpliﬁed comparison to the data
(Fig. 3) but was not used for the statistical analysis described
below. However, the results were essentially the same as the
“single copy” simulation model. The liver was observed to grow
approximately linearly during the observed time period, hence the
liver size L at time t is taken to be L¼αþβ t, where α is the initial
liver size and β is the rate of liver growth (the assumption of linear
growth is not essential, but is used here to simplify the presenta-
tion). Infected cells (I), equivalent to cccDNA copies, then decline at
the rate dI/dt¼β f(I/L), where f is the fraction of infected cells
that lose their single copy of cccDNA when undergoing mitosis.
Uninfected cells (U) grow at the rate dU/dt¼β(U/Lþ(1þβ)I/L). The
two rates sum to the liver growth rate
dL=dt ¼ ðdI=dtþdU=dtÞ ¼β  f ðI=LÞþβðU=Lþð1þ f ÞI=LÞ
¼ βðUþ IÞ=L¼ β:
Substituting L from the ﬁrst equation into the second, then
separating variables, yields the solution
I¼ I0ðL0=ðL0þβ  tÞÞf ;
where I0 and L0 are the values of I and L at t¼0. Then, solving for
f¼0, I¼ I0. Normalizing to the fraction of infected cells per liver,
I/L¼ I0(L0/L). Likewise, for f¼1, I¼ I0(L0/(L0þβ t))¼ I0(L0/L), and
normalizing to fraction of infected cells per liver, I/L¼(I0(L0/L))/
L¼ I0(L0/L2). Since I is the same as the amount of cccDNA (C) per
liver, the fractional decline in cccDNA from day 1 p.i., I/I0¼C/C0,
will drop as (L0/L) for f¼0, and as (L0/L2) for f¼1.
Simulation model: “single copy” assumption
Duckling liver was simulated to have 20,000 hepatocytes at the
start of day 1 p.i. Each day, 11,084 cells were selected at random
and simulated to proliferate. This ﬁgure was selected so that the
ratio of liver mass at 42 days to that on day 1 p.i. matched the
observed data. Allowing hepatocytes to divide at most once, twice,
or multiple times per day did not have a signiﬁcant effect on the
outcome. If a cell selected to divide is uninfected, then two
uninfected progeny cells are produced. If the cell was infected
then one progeny cell will be uninfected and the other progeny
cell may lose its cccDNA with probability f. In the latter case both
progeny cells are uninfected, otherwise the single cccDNA copy is
retained in one progeny cell. The random selection is done one cell
at a time with progeny cells added to the pool of cells. On day 42 p.
i., the simulated liver contains 475,528 cells, an 23-fold increase
in liver mass from day 1 p.i. In each case the daily linear growth of
the liver was maintained for 42 days. The fraction of cccDNA
copies lost on mitosis, f, is entered at run time. Model output is the
total daily number of cccDNA molecules divided by the total
number of hepatocytes. The model was adjusted so that the
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average copies of cccDNA per hepatocyte on day 1 p.i. matched the
measured amount. The average amount of cccDNA per hepatocyte
predicted for days 7, 14, 21, 28, 35 and 42 was compared to the
observed amounts of cccDNA per hepatocyte on those days. The
corresponding number of duck livers measured on each day was 3,
3, 3, 2, 3, and 3. Levels of cccDNA in duck 17 (Table 1) were
signiﬁcantly outside the range of values obtained with the other
ducks and were not included in this analysis.
Simulation model: “Poisson” assumption
Under this model, the cells were assumed to have a “Poisson”
distributed number of cccDNA copies by day 1 p.i., all received
from the inoculated virus. The model was adjusted to ﬁt the data
for the average amount of cccDNA per hepatocyte present at day
1 p.i. (Table 1). Liver growth was as described in the single-copy
model. f is the fraction of cccDNA copies lost on mitosis. The only
difference between this model and the “single-copy” model is the
method of copy distribution when cells divide. When an infected
cell divides each cccDNA copy is independently lost on mitosis
with probability f. Thus, if a parent cell contained n copies of
cccDNA, the number of copies lost would be binomially distributed
with probability f, that is
pðj copies disributedjn; f Þ ¼ ðnj Þf jð1f ÞnjÞ
Each copy of cccDNA that is not lost is distributed to the two
progeny cells with equal probability, (1/2).
Data: comparison to models
The models were initially run with f¼0, to simulate survival
(no loss) of cccDNA during mitosis (Figs. S1A and S1C). Using f¼0
as the null hypothesis, we compared model outputs at the six
observed time points. Under the null hypothesis we would expect
half of the observations to fall below the corresponding model
predictions. Nine of the observations were less than their corre-
sponding model predictions while eight were greater. This being
about half, the null hypothesis (survival of cccDNA) cannot be
rejected (Figs. S1A and S1C).
In particular, under the hypothesis that 50% of the data will be
below and 50% above the line, the number of data points falling
below the prediction will be binomially distributed as
bðk;n; pÞ ¼ ðnk Þpkð1pÞnk
where k is the number of data points falling below the curve, n is
the number of observations and p¼1/2 is the chance that an
observation falls below the computed prediction In this case b(k n
p) becomes
bðk;17;1=2Þ ¼ ð17k Þ=217
nine of the 17 data points fell below the prediction. The chance
that nine or fewer observations fall below the curve is
pð0rkr9Þ ¼ ∑
9
k ¼ 0
bðk;17;1=2Þ ¼ 0:685
Assuming each data point to be independent (all 17 were
obtained from different animals) this gives a binomial p-value of
0.68. Thus the data are compatible with the hypothesis of survival
(no loss) of cccDNA during mitosis.
To test this further, we adjusted the models for increasing
values of f. We found that we could reject, with either simulation
model, the hypothesis that f is equal to or greater than 0.49
(Figs. S1B and S1D) with a p-value of 0.0245. The p-value is
reduced to 0.0015 if we assume a maximum estimated daily cell
death rate of 2% (analysis not shown). Thus, the data are compa-
tible with the model that at least 49% of cccDNA survives mitosis.
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